Drug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses

dc.authoridIslam, Tania/0000-0002-2254-7758
dc.authoridTURANLI, Beste/0000-0003-1330-9712
dc.authoridArga, Kazim Yalcin/0000-0002-6036-1348
dc.contributor.authorIslam, Tania
dc.contributor.authorRahman, Md Rezanur
dc.contributor.authorGov, Esra
dc.contributor.authorTuranli, Beste
dc.contributor.authorGulfidan, Gizem
dc.contributor.authorHaque, Md Anwarul
dc.contributor.authorArga, Kazim Yalcin
dc.date.accessioned2025-01-06T17:38:20Z
dc.date.available2025-01-06T17:38:20Z
dc.date.issued2018
dc.description.abstractThe head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world, but robust biomarkers and diagnostics are still not available. This study provides in-depth insights from systems biology analyses to identify molecular biomarker signatures to inform systematic drug targeting in HNSCC. Gene expression profiles from tumors and normal tissues of 22 patients with histological confirmation of nonmetastatic HNSCC were subjected to integrative analyses with genome-scale biomolecular networks (i.e., protein-protein interaction and transcriptional and post-transcriptional regulatory networks). We aimed to discover molecular signatures at RNA and protein levels, which could serve as potential drug targets for therapeutic innovation in the future. Eleven proteins, 5 transcription factors, and 20 microRNAs (miRNAs) came into prominence as potential drug targets. The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq datasets, and risk discrimination performance of the reporter biomolecules, BLNK, CCL2, E4F1, FOSL1, ISG15, MMP9, MYCN, MYH11, miR-1252, miR-29b, miR-29c, miR-3610, miR-431, and miR-523, was also evaluated. Using the transcriptome guided drug repositioning tool, geneXpharma, several candidate drugs were repurposed, including antineoplastic agents (e.g., gemcitabine and irinotecan), antidiabetics (e.g., rosiglitazone), dermatological agents (e.g., clocortolone and acitretin), and antipsychotics (e.g., risperidone), and binding affinities of the drugs to their potential targets were assessed using molecular docking analyses. The molecular signatures and repurposed drugs presented in this study warrant further attention for experimental studies since they offer significant potential as biomarkers and candidate therapeutics for precision medicine approaches to clinical management of HNSCC.
dc.description.sponsorshipTUBITAK [116 M014]
dc.description.sponsorshipThe authors are grateful to the Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia, Bangladesh and Laboratory of Bioinformatics, Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh for providing the research facility. This work was supported by TUBITAK through project 116 M014.
dc.identifier.doi10.1089/omi.2018.0048
dc.identifier.endpage436
dc.identifier.issn1536-2310
dc.identifier.issn1557-8100
dc.identifier.issue6
dc.identifier.pmid29927717
dc.identifier.scopus2-s2.0-85049061035
dc.identifier.scopusqualityQ2
dc.identifier.startpage422
dc.identifier.urihttps://doi.org/10.1089/omi.2018.0048
dc.identifier.urihttps://hdl.handle.net/20.500.14669/2545
dc.identifier.volume22
dc.identifier.wosWOS:000435827100004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofOmics-A Journal of Integrative Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241211
dc.subjecthead and neck squamous cell carcinoma
dc.subjectsystems biology
dc.subjectbioinformatics
dc.subjectdrug repurposing
dc.subjectbiomarkers
dc.titleDrug Targeting and Biomarkers in Head and Neck Cancers: Insights from Systems Biology Analyses
dc.typeArticle

Dosyalar